UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Open public recruiting
Unique ID issued by UMIN UMIN000028553
Receipt No. R000032676
Scientific Title Efficacy of 0.01% Atropine Ophthalmic Solution on Myopia Progression and Axial Elongation of the Eye in School Children with High- or Moderate-grade Myopia
Date of disclosure of the study information 2017/09/15
Last modified on 2019/03/13

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Efficacy of 0.01% Atropine Ophthalmic Solution on Myopia Progression and Axial Elongation of the Eye in School Children with High- or Moderate-grade Myopia
Acronym Efficacy of 0.01% Atropine Ophthalmic Solution on Myopia Progression and Axial Elongation of the Eye in School Children with High- or Moderate-grade Myopia
Scientific Title Efficacy of 0.01% Atropine Ophthalmic Solution on Myopia Progression and Axial Elongation of the Eye in School Children with High- or Moderate-grade Myopia
Scientific Title:Acronym Efficacy of 0.01% Atropine Ophthalmic Solution on Myopia Progression and Axial Elongation of the Eye in School Children with High- or Moderate-grade Myopia
Region
Japan

Condition
Condition high- or moderate-grade myopia
Classification by specialty
Ophthalmology Child
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To estimate the efficacy of 0.01% atropine ophthalmic solution on myopia progression and axial elongation of the eye in the school children diagnosed with high- or moderate-grade myopia
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Change in objectively-measured spherical equivalent refraction and axial length of the eye during the follow-up period of 12 months
Key secondary outcomes

Base
Study type Interventional

Study design
Basic design Cross-over
Randomization Randomized
Randomization unit Individual
Blinding Open -but assessor(s) are blinded
Control No treatment
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 2
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 daily application of 0.01% atropine ophthalmic solution to the both eyes for 12 months
Interventions/Control_2 spectacle correction only
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
6 years-old <=
Age-upper limit
12 years-old >=
Gender Male and Female
Key inclusion criteria (1) Children aged 6 to 12 years at the time of consent

(2) Children with spherical equivalent refraction of -4.50 to-9.00 D in each eye

(3) Children with anisometropia within 1.50 D.

(4) Children with astigmatism within +/-1.50 D

(5) Children with corrected visual acuity of at least 1.0

(6) Children with intraocular pressure equal
to or lower than 21mmHg

(7) Children capable of undergoing cycloplegia

(8) Children who can undergo outpatient examinations per protocol

(9) Written informed consent to participate in the study obtained from the child personally and a person with parental authority
Key exclusion criteria (1) Children with abnormal binocular function

(2) Children with amblyopia or manifest strabismus

(3) Children with ocular disorders other than myopia

(4) Children with ocular or systemic disorders that potentially affect myopia or refractive power

(5) Children who have received previous treatment for myopia control that included atropine therapy, bifocal lenses, progressive lenses, and Ortho-K.

(6) Children with a history of cardiovascular or respiratory disease

(7) Children who have received pharmacotherapy for asthma in the past year

(8) Children with allergy to atropine, cyclopentolate, or benzalkonium

(9) Children who cannot use eye drops

(10) Children who plans to use contact lenses during the follow-up period
Target sample size 50

Research contact person
Name of lead principal investigator
1st name Satoshi
Middle name
Last name Hasebe
Organization Kawasaki Medical School
Division name Department of Ophthalmology 2
Zip code 700-8505
Address 2-6-1 Nakasange, Kita-ku, Okayama
TEL 086-225-2111
Email shasebe2009@yahoo.co.jp

Public contact
Name of contact person
1st name Hasebe
Middle name
Last name Satoshi
Organization Kawasaki Medical School
Division name Department of Ophthalmology 2
Zip code 700-8558
Address 2-6-1 Nakasange, Kita-ku, Okayama
TEL 086-225-2111
Homepage URL https://g.kawasaki-m.ac.jp/dept/ganka/ekigaku
Email shasebe2009@yahoo.co.jp

Sponsor
Institute Kawasaki Medical School
Department of Ophthalmology 2
Institute
Department

Funding Source
Organization Ministry of Education, Culture, Sports, Science and Technology, and Kawasaki Medical School
Organization
Division
Category of Funding Organization Japanese Governmental office
Nationality of Funding Organization Japan

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences and Okayama University Hospital, Ethics Committee
Address 2-5-1 Shikata-cho, Kita-ku, Okayama
Tel 086-235-6938
Email mae6605@adm.okayama-u.ac.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 川崎医科大学総合医療センター(岡山県)

Other administrative information
Date of disclosure of the study information
2017 Year 09 Month 15 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Open public recruiting
Date of protocol fixation
2017 Year 08 Month 01 Day
Date of IRB
2017 Year 10 Month 16 Day
Anticipated trial start date
2018 Year 03 Month 15 Day
Last follow-up date
2020 Year 12 Month 31 Day
Date of closure to data entry
2020 Year 12 Month 31 Day
Date trial data considered complete
2020 Year 12 Month 31 Day
Date analysis concluded
2021 Year 06 Month 15 Day

Other
Other related information

Management information
Registered date
2017 Year 08 Month 06 Day
Last modified on
2019 Year 03 Month 13 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000032676

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.